These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 20368574)

  • 1. Development of a multimarker assay for early detection of ovarian cancer.
    Yurkovetsky Z; Skates S; Lomakin A; Nolen B; Pulsipher T; Modugno F; Marks J; Godwin A; Gorelik E; Jacobs I; Menon U; Lu K; Badgwell D; Bast RC; Lokshin AE
    J Clin Oncol; 2010 May; 28(13):2159-66. PubMed ID: 20368574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A step forward for two-step screening for ovarian cancer.
    Hensley ML
    J Clin Oncol; 2010 May; 28(13):2128-30. PubMed ID: 20368556
    [No Abstract]   [Full Text] [Related]  

  • 3. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer.
    Yang WL; Lu Z; Guo J; Fellman BM; Ning J; Lu KH; Menon U; Kobayashi M; Hanash SM; Celestino J; Skates SJ; Bast RC
    Cancer; 2020 Feb; 126(4):725-736. PubMed ID: 31714597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.
    Nolen B; Velikokhatnaya L; Marrangoni A; De Geest K; Lomakin A; Bast RC; Lokshin A
    Gynecol Oncol; 2010 Jun; 117(3):440-5. PubMed ID: 20334903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
    PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bead-based ELISA for validation of ovarian cancer early detection markers.
    Scholler N; Crawford M; Sato A; Drescher CW; O'Briant KC; Kiviat N; Anderson GL; Urban N
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2117-24. PubMed ID: 16609024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
    Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
    Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases.
    Molina R; Escudero JM; Augé JM; Filella X; Foj L; Torné A; Lejarcegui J; Pahisa J
    Tumour Biol; 2011 Dec; 32(6):1087-95. PubMed ID: 21863264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
    Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
    Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
    Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
    Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma.
    Chang X; Ye X; Dong L; Cheng H; Cheng Y; Zhu L; Liao Q; Zhao Y; Tian L; Fu T; Chen J; Cui H
    Int J Gynecol Cancer; 2011 Jul; 21(5):852-8. PubMed ID: 21633297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Improved Prediction Model for Ovarian Cancer Using Urinary Biomarkers and a Novel Validation Strategy.
    Lee SW; Lee HY; Bang HJ; Song HJ; Kong SW; Kim YM
    Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31590408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
    Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
    Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass.
    Moore RG; Miller MC; Disilvestro P; Landrum LM; Gajewski W; Ball JJ; Skates SJ
    Obstet Gynecol; 2011 Aug; 118(2 Pt 1):280-288. PubMed ID: 21775843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm.
    Van Gorp T; Cadron I; Despierre E; Daemen A; Leunen K; Amant F; Timmerman D; De Moor B; Vergote I
    Br J Cancer; 2011 Mar; 104(5):863-70. PubMed ID: 21304524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.
    Clarke CH; Yip C; Badgwell D; Fung ET; Coombes KR; Zhang Z; Lu KH; Bast RC
    Gynecol Oncol; 2011 Sep; 122(3):548-53. PubMed ID: 21708402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer.
    Simmons AR; Clarke CH; Badgwell DB; Lu Z; Sokoll LJ; Lu KH; Zhang Z; Bast RC; Skates SJ
    Int J Gynecol Cancer; 2016 Jul; 26(6):1070-7. PubMed ID: 27206285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.
    Shah CA; Lowe KA; Paley P; Wallace E; Anderson GL; McIntosh MW; Andersen MR; Scholler N; Bergan LA; Thorpe JD; Urban N; Drescher CW
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1365-72. PubMed ID: 19423517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm.
    Ruggeri G; Bandiera E; Zanotti L; Belloli S; Ravaggi A; Romani C; Bignotti E; Tassi RA; Tognon G; Galli C; Caimi L; Pecorelli S
    Clin Chim Acta; 2011 Jul; 412(15-16):1447-53. PubMed ID: 21557935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.